Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jing-yuan-kang Granule in Lung Adenocarcinoma
NCT04482829Unknown
- Sponsor
- Henan University of Chinese Medicine
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of Jing-yuan-kang in lung adenocarcinoma (2 arms), sponsored by Henan University of Chinese Medicine. Primary endpoints: Quality of Life (EORTC QLQ-C30) at 12 weeks and Quality of Life (QLQ-LC13) at 12 weeks. Status: unknown.
02
Drugs
Jing-yuan-kang
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT04482829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482829.